Nuclear translocation and activation of YAP by hypoxia contributes to the chemoresistance of SN38 in hepatocellular carcinoma cells
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
// Xiao-Yang Dai 1, 2, * , Lin-Han Zhuang 1, * , Dan-Dan Wang 1, * , Tian-Yi Zhou 1 , Lin-Lin Chang 1 , Ren-Hua Gai 2 , Di-Feng Zhu 2 , Bo Yang 1 , Hong Zhu 1 , Qiao-Jun He 1 1 Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China 2 Center for Drug Safety Evaluation and Research of Zhejiang University, Hangzhou 310058, China * These authors contributed equally to this work Correspondence to: Hong Zhu, e-mail: hongzhu@zju.edu.cn Qiao-Jun He, e-mail: qiaojunhe@zju.edu.cn Keywords: hepatocellular carcinoma, SN38, hypoxia, resistance, yes-associated protein (YAP) Received: June 23, 2015 Accepted: December 29, 2015 Published: January 12, 2016 ABSTRACT Although hypoxia is a prominent feature contributing to the therapeutic resistance of hepatocellular carcinoma cells (HCC) against chemotherapeutic agents, including the Topoisomerase I inhibitor SN38, the underlying mechanism is not fully understood and its understanding remains a major clinical challenge. In the present study, we found that hypoxia-induced nuclear translocation and accumulation of YAP acted as a survival input to promote resistance to SN38 in HCC. The induction of YAP by hypoxia was not mediated by HIF-1α because manipulating the abundance of HIF-1α with CoCl2, exogenous expression, and RNA interference had no effect on the phosphorylation or total levels of YAP. The mevalonate-HMG-CoA reductase (HMGCR) pathway may modulate the YAP activation under hypoxia. Combined YAP inhibition using either siRNA or the HMGCR inhibitor statins together with SN38 treatment produced improved anti-cancer effects in HCC cells. The increased anti-cancer effect of the combined treatment with statins and irinotecan (the prodrug of SN-38) was further validated in a human HepG2 xenograft model of HCC in nude mice. Taken together, our findings identify YAP as a novel mediator of hypoxic-resistance to SN38. These results suggest that the administration of SN28 together with the suppression of YAP using statins is a promising strategy for enhancing the treatment response in HCC patients, particularly in advanced stage HCC cases presenting hypoxic resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhao, B., Wei, X., Li, W., Udan, R. S., Yang, Q., Kim, J., Xie, J., Ikenoue, T., Yu, J., Li, L., et al. (2007) · Genes & Development · doi:10.1101/gad.1602907 · Cited by 3,092 · cited 2×
“Recent studies reported that YAP overexpression and activation is correlated with poor prognosis of cancer patients [18, 40], likely because it promotes tumor progression [27, 41] and/or metastasis [42–44].”
BackgroundTEAD mediates YAP-dependent gene induction and growth control
Zhao, B., Ye, X., Yu, J., Li, L., Li, W., Li, S., Yu, J., Lin, J. D., Wang, C.-Y., Chinnaiyan, A. M., et al. (2008) · Genes & Development · doi:10.1101/gad.1664408 · Cited by 2,498
HIF-1: mediator of physiological and pathophysiological responses to hypoxia
Semenza, G. L. (2000) · Journal of Applied Physiology · doi:10.1152/jappl.2000.88.4.1474 · Cited by 1,822 · cited 1×
“It has been considered that the major regulator of cellular adaptation to hypoxia is the hypoxiainducible factor-1 (HIF-1) [5–8], whose contribution to chemoresistance has been demonstrated in a variety of cancer cell models, particularly in HCC cells [9–11].”
BackgroundWeidemann, A., & Johnson, R. S. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.12 · Cited by 941
Basu, S., Totty, N. F., Irwin, M. S., Sudol, M., & Downward, J. (2003) · Molecular Cell · doi:10.1016/s1097-2765(02)00776-1 · Cited by 843
Regulation of hypoxia-inducible factor-1α by NF-κB
van Uden, P., Kenneth, N. S., & Rocha, S. (2008) · Biochemical Journal · doi:10.1042/bj20080476 · Cited by 729
Vassilev, A., Kaneko, K. J., Shu, H., Zhao, Y., & DePamphilis, M. L. (2001) · Genes & Development · doi:10.1101/gad.888601 · Cited by 719 · cited 1×
“As a transcriptional co-factor, the nuclear YAP initiates the transcription by interacting with the DNA-binding transcription factors EA domain family members 1–4 (TEAD1-4) [24–26].”
BackgroundWu, S., Liu, Y., Zheng, Y., Dong, J., & Pan, D. (2008) · Developmental Cell · doi:10.1016/j.devcel.2008.01.007 · Cited by 640 · cited 1×
“As a transcriptional co-factor, the nuclear YAP initiates the transcription by interacting with the DNA-binding transcription factors EA domain family members 1–4 (TEAD1-4) [24–26].”
BackgroundThe TEAD/TEF family of transcription factor Scalloped mediates Hippo signaling in organ size control
Zhang, L., Ren, F., Zhang, Q., Chen, Y., Wang, B., & Jiang, J. (2008) · Developmental Cell · doi:10.1016/j.devcel.2008.01.006 · Cited by 630 · cited 1×
“As a transcriptional co-factor, the nuclear YAP initiates the transcription by interacting with the DNA-binding transcription factors EA domain family members 1–4 (TEAD1-4) [24–26].”
BackgroundCellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway
Mo, J.-S., Meng, Z., Kim, Y. C., Park, H. W., Hansen, C. G., Kim, S., Lim, D.-S., & Guan, K.-L. (2015) · Nature Cell Biology · doi:10.1038/ncb3111 · Cited by 557
Cited by
YAP/TAZ Signaling and Resistance to Cancer Therapy
Nguyen, C. D. K., & Yi, C. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.02.010 · Cited by 437
Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors
Méndez-Blanco, C., Fondevila, F., García-Palomo, A., González-Gallego, J., & Mauriz, J. L. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0159-1 · Cited by 339
Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance
Bar-Zeev, M., Livney, Y. D., & Assaraf, Y. G. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.05.002 · Cited by 314
YAP/TAZ Signaling as a Molecular Link between Fibrosis and Cancer
Noguchi, S., Saito, A., & Nagase, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113674 · Cited by 277
Endothelial YAP/TAZ Signaling in Angiogenesis and Tumor Vasculature
Hooglugt, A., van der Stoel, M. M., Boon, R. A., & Huveneers, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.612802 · Cited by 82
Targeting post-translational modification of transcription factors as cancer therapy
Qian, M., Yan, F., Yuan, T., Yang, B., He, Q., & Zhu, H. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.06.005 · Cited by 47
Self-citation
Metadata
- Authors
- Dai, X.-Y., Zhuang, L.-H., Wang, D.-D., Zhou, T.-Y., Chang, L.-L., Gai, R.-H., Zhu, D.-F., Yang, B., Zhu, H., & He, Q.-J.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-01-12
- Volume
- 7
- Issue
- 6
- Pages
- 6933-6947
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2299368506
- Cited by
- 72
- References
- 17
- FWCI
- 6.84
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.